A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

BACKGROUND: Alzheimer’s disease (AD) is the most common form of dementia, the number of affected individuals is rising, with significant impacts for healthcare systems. Current symptomatic treatments delay, but do not halt, disease progression. Genetic evidence points to aggregation and deposition o...

Descripción completa

Detalles Bibliográficos
Autores principales: Neumann, Ulf, Rueeger, Heinrich, Machauer, Rainer, Veenstra, Siem Jacob, Lueoend, Rainer M., Tintelnot-Blomley, Marina, Laue, Grit, Beltz, Karen, Vogg, Barbara, Schmid, Peter, Frieauff, Wilfried, Shimshek, Derya R., Staufenbiel, Matthias, Jacobson, Laura H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559881/
https://www.ncbi.nlm.nih.gov/pubmed/26336937
http://dx.doi.org/10.1186/s13024-015-0033-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559881/
https://www.ncbi.nlm.nih.gov/pubmed/26336937
http://dx.doi.org/10.1186/s13024-015-0033-8

Ejemplares similares